2.38
0.27 (12.80%)
| Previous Close | 2.11 |
| Open | 2.14 |
| Volume | 627,919 |
| Avg. Volume (3M) | 241,125 |
| Market Cap | 63,129,740 |
| Price / Sales | 255.50 |
| Price / Book | 16.15 |
| 52 Weeks Range | |
| Earnings Date | 24 Mar 2025 - 28 Mar 2025 |
| Diluted EPS (TTM) | -0.830 |
| Total Debt/Equity (MRQ) | 10.50% |
| Current Ratio (MRQ) | 2.22 |
| Operating Cash Flow (TTM) | -19.11 M |
| Levered Free Cash Flow (TTM) | -10.84 M |
| Return on Assets (TTM) | -97.10% |
| Return on Equity (TTM) | -290.21% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Gain Therapeutics, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.25 |
|
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.78% |
| % Held by Institutions | 8.14% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 9.00 (BTIG, 278.15%) | Buy |
| Median | 8.00 (236.13%) | |
| Low | 6.00 (Roth Capital, 152.10%) | Buy |
| Average | 7.67 (222.27%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 1.66 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 08 Sep 2025 | 9.00 (278.15%) | Buy | 1.75 |
| Roth Capital | 13 Aug 2025 | 6.00 (152.10%) | Buy | 1.55 |
| HC Wainwright & Co. | 03 Jul 2025 | 8.00 (236.13%) | Buy | 1.69 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Sep 2025 | Announcement | Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation |
| 12 Aug 2025 | Announcement | Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update |
| 24 Jul 2025 | Announcement | Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference |
| 16 Jul 2025 | Announcement | Gain Therapeutics Announces Pricing of $7.0 Million Public Offering |
| 15 Jul 2025 | Announcement | Gain Therapeutics Announces Proposed Public Offering |
| 30 Jun 2025 | Announcement | Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |